XTX Topco Ltd Purchases Shares of 2,115 Amgen Inc. (NASDAQ:AMGN)

XTX Topco Ltd purchased a new stake in Amgen Inc. (NASDAQ:AMGN) in the 2nd quarter, Holdings Channel reports. The firm purchased 2,115 shares of the medical research company’s stock, valued at approximately $661,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Concorde Asset Management LLC grew its holdings in Amgen by 4.8% in the 2nd quarter. Concorde Asset Management LLC now owns 888 shares of the medical research company’s stock valued at $277,000 after buying an additional 41 shares during the period. MRP Capital Investments LLC purchased a new stake in Amgen in the 2nd quarter valued at about $219,000. Marathon Trading Investment Management LLC purchased a new stake in Amgen in the 2nd quarter valued at about $469,000. Seven Eight Capital LP purchased a new stake in Amgen in the 2nd quarter valued at about $845,000. Finally, Lokken Investment Group LLC grew its holdings in Amgen by 13.6% in the 2nd quarter. Lokken Investment Group LLC now owns 3,742 shares of the medical research company’s stock valued at $1,169,000 after buying an additional 449 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Argus boosted their target price on Amgen from $300.00 to $340.00 and gave the stock a “buy” rating in a report on Thursday, June 27th. Royal Bank of Canada upped their price target on Amgen from $332.00 to $362.00 and gave the stock an “outperform” rating in a report on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $305.00 price target (down previously from $310.00) on shares of Amgen in a report on Wednesday, August 7th. Wells Fargo & Company cut Amgen from an “overweight” rating to an “equal weight” rating and upped their price target for the stock from $320.00 to $335.00 in a report on Wednesday, August 7th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $380.00 target price (up from $375.00) on shares of Amgen in a research report on Wednesday, August 7th. Eleven equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $327.28.

Amgen Price Performance

Shares of NASDAQ AMGN opened at $335.61 on Tuesday. Amgen Inc. has a 1-year low of $249.70 and a 1-year high of $346.85. The company has a debt-to-equity ratio of 9.64, a current ratio of 1.26 and a quick ratio of 0.89. The business’s fifty day moving average price is $329.68 and its two-hundred day moving average price is $306.47. The firm has a market capitalization of $180.03 billion, a PE ratio of 47.94, a P/E/G ratio of 2.93 and a beta of 0.61.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.01 by ($0.04). Amgen had a return on equity of 161.72% and a net margin of 10.12%. The business had revenue of $8.39 billion during the quarter, compared to the consensus estimate of $8.35 billion. During the same period in the previous year, the company posted $5.00 EPS. The company’s revenue for the quarter was up 20.1% compared to the same quarter last year. On average, research analysts expect that Amgen Inc. will post 19.49 EPS for the current year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, August 6th. Investors of record on Friday, August 16th were paid a dividend of $2.25 per share. The ex-dividend date of this dividend was Friday, August 16th. This represents a $9.00 annualized dividend and a yield of 2.68%. Amgen’s dividend payout ratio is currently 128.57%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.